The effect of switching to Eldecalcitol from Alfacalcidol on osteoporosis caused by Anastrozole / Letrozole for post-operative breast cancer.

The effect of switching to Eldecalcitol from Alfacalcidol on osteoporosis caused by Anastrozole / Letrozole for post-operative breast cancer. - The effect of switching to Eldecalcitol from Alfacalcidol on osteoporosis caused by Anastrozole / Letrozole for post-operative breast cancer.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000009182

Enrollment

Registered

2012-10-26

Start date

2012-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Secondary osteoporosis

Interventions

Eldecalcitol (0.75&amp

micro

g/day)

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1. Post-operative mammary carcinoma patients whose TNM stage from 0 to IIIA and under receiving anastrozole. 2. Patients with more than 3 years after menopause. 3. Patients with less than -1.0 T score of lumber or total femoral BMD, or with fragile vertebral fractures. 4. Outpatients 5. Patients acquired informed consent about this study.

Exclusion criteria

Exclusion criteria: 1. Using other osteoporosis drugs except alfacalcidol within 6 months. 2. Patients suffered from malignancies except mammary carcinoma. 3. Patients with contraindication for eldecalcitol treatments 4. Patients who have serum calcium levels of above 10.4mg/dL. 5. Patients judged inappropriate by attending physicians.

Design outcomes

Primary

Measure	Time frame
Change from baseline to 12 months in lumbar spine BMD	—

Secondary

Measure	Time frame
bone turnover marker(TRACP-5b), QOL(QOL-ACD,QOL-ACD-B) incidence of fracture (vertebral fractures, non- vertebral fractures), blood calcium urinary calcium creatinine rate of breast cancer recurrence	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026